Drug intelligence / Profile preview

VRVg-2 + human rabies immunoglobulins

Development stage
Unknown
Lead developer
Sanofi
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

**VRVg-2 + human rabies immunoglobulins** is a combination regimen used for rabies post-exposure prophylaxis, consisting of VRVg-2, a purified, inactivated rabies vaccine prepared on Vero cell line (serum-free), and human rabies immunoglobulins (HRIG). VRVg-2 induces active immunity by introducing inactivated rabies virus antigens, stimulating the production of rabies virus neutralizing antibodies. HRIG provides immediate passive immunization by supplying preformed antibodies that can neutralize the virus before the body has mounted its own immune response. This combined approach is standard in rabies post-exposure prophylaxis, where vaccine administration is accompanied by HRIG to bridge the immunity gap until a sufficient vaccine-derived immune response develops[3].

Brand names
Verorab
Other names
purified vero rabies vaccine + human rabies immunoglobulinsVRVg-2 + HRIG
02

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on VRVg-2 + human rabies immunoglobulins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRVg-2 + human rabies immunoglobulins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call